Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy
about
The Role of Proteomics in Biomarker Development for Improved Patient Diagnosis and Clinical Decision Making in Prostate CancerRadiation Therapy after Radical Prostatectomy: Implications for CliniciansThe Present and Future of Biomarkers in Prostate Cancer: Proteomics, Genomics, and Immunology AdvancementsIncorporation of tissue-based genomic biomarkers into localized prostate cancer clinicsMechanistic Insights into Molecular Targeting and Combined Modality Therapy for Aggressive, Localized Prostate CancerGenomic and Histopathological Tissue Biomarkers That Predict Radiotherapy Response in Localised Prostate CancerWhat is the Need for Prostatic Biomarkers in Prostate Cancer Management?How Precisely Can Prostate Cancer Be Managed?Human phosphodiesterase 4D7 (PDE4D7) expression is increased in TMPRSS2-ERG-positive primary prostate cancer and independently adds to a reduced risk of post-surgical disease progressionA novel miRNA-based predictive model for biochemical failure following post-prostatectomy salvage radiation therapySuppression of LIM and SH3 Domain Protein 1 (LASP1) Negatively Regulated by Androgen Receptor Delays Castration Resistant Prostate Cancer Progression.An update on the LIM and SH3 domain protein 1 (LASP1): a versatile structural, signaling, and biomarker proteinLoss of tumor suppressor mir-203 mediates overexpression of LIM and SH3 Protein 1 (LASP1) in high-risk prostate cancer thereby increasing cell proliferation and migration.Prognostic outlier genes for enhanced prostate cancer treatment.Reconsidering adjuvant versus salvage radiation therapy for prostate cancer in the genomics era.Genomic prostate cancer classifier predicts biochemical failure and metastases in patients after postoperative radiation therapyEvaluating the clinical impact of a genomic classifier in prostate cancer using individualized decision analysis.Evolving transcriptomic fingerprint based on genome-wide data as prognostic tools in prostate cancerCancer/Testis Antigens: "Smart" Biomarkers for Diagnosis and Prognosis of Prostate and Other CancersMolecular classification of prostate adenocarcinoma by the integrated somatic mutation profiles and molecular networkFamily with sequence similarity 13C (FAM13C) overexpression is an independent prognostic marker in prostate cancer.Neuropilin-1 is upregulated in the adaptive response of prostate tumors to androgen-targeted therapies and is prognostic of metastatic progression and patient mortality.Lipid degradation promotes prostate cancer cell survival.Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population.Emerging proteomics biomarkers and prostate cancer burden in Africa.Copy number alteration burden predicts prostate cancer relapseTranslating RNA sequencing into clinical diagnostics: opportunities and challenges.Therapy-induced developmental reprogramming of prostate cancer cells and acquired therapy resistance.Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohortA genomic classifier predicting metastatic disease progression in men with biochemical recurrence after prostatectomyEffect of a genomic classifier test on clinical practice decisions for patients with high-risk prostate cancer after surgeryGene Expression Profiling of Ewing Sarcoma Tumors Reveals the Prognostic Importance of Tumor-Stromal Interactions: A Report from the Children's Oncology GroupThe prognostic value of SUMO1/Sentrin specific peptidase 1 (SENP1) in prostate cancer is limited to ERG-fusion positive tumors lacking PTEN deletionSpecific and redundant activities of ETV1 and ETV4 in prostate cancer aggressiveness revealed by co-overexpression cellular contextsDysregulation of the vascular endothelial growth factor and semaphorin ligand-receptor families in prostate cancer metastasis.Comparing Platforms for Messenger RNA Expression Profiling of Archival Formalin-Fixed, Paraffin-Embedded Tissues.A 22 Gene-expression Assay, Decipher® (GenomeDx Biosciences) to Predict Five-year Risk of Metastatic Prostate Cancer in Men Treated with Radical ProstatectomyMolecular characterization of Gleason patterns 3 and 4 prostate cancer using reverse Warburg effect-associated genesRNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SChLAP1.Characterization of 1577 primary prostate cancers reveals novel biological and clinicopathologic insights into molecular subtypes.
P2860
Q26738703-13B6A527-1712-40B7-93CE-412854CCD1CAQ26744531-CAFDC5C3-11DA-40EA-B706-A3C205D7BE67Q26750672-4E355983-A367-4C5E-A9EC-1BC9990511BDQ26752510-7650F6D2-BC73-4FC3-A311-FA348A9643B0Q26766638-EC77B460-94EC-44FE-9310-253EA1988E96Q26778586-4ACEB4D5-0FA4-493D-A9A4-4397272A944BQ26798425-76217F89-9AA3-467A-84E5-A5387172875FQ28078942-9B6C4C11-033F-4EED-935D-D9F42171C779Q28269917-7C694B29-5ADF-405E-BAD4-8A14969AEE6FQ28543958-7345C469-76CD-437A-A087-D6E237FC4635Q30008838-C48CA9C7-B935-440C-8802-08D033DD528BQ30009240-EFC0043A-814F-41F8-B8BC-D0EC6D0E9C2DQ30009388-10590B4E-C18C-49F8-9166-31BB6E611607Q30244674-1751C897-8257-459C-BAD2-71A6FF672EA3Q30276626-FECE5CAB-7F8B-48E4-9CF1-FB3F0327F10FQ30371634-B37B4FC1-1E38-4C65-B69F-E4699C55376BQ30405851-3C15DCFF-073F-40A6-9EFF-3CFD4852D53CQ30938412-2AD68370-A918-41C7-B238-B14B629BAFABQ33624448-BDF030DC-A8B4-47CA-88FB-73AC0958866AQ33677773-A288DA95-BD04-4EAF-A11B-BECBC7CA9B7CQ33761801-41C506CF-6E64-41C4-BF1C-7AC84A9F7094Q33835918-A08DCA15-C286-4277-9BFF-B0A687E8DE82Q33888770-629285C2-6092-42E8-A09C-EA7E9F950620Q33898869-A19B977A-6941-43C1-9823-67C8410702DFQ33914221-FA98EAFB-57B4-45FF-A7EE-6834D0212DBBQ34002312-658DCAFD-CDFB-482A-A472-CE424282921FQ34519034-26CD4B7B-C46C-438F-8684-DB31F312C229Q34550412-510C42D1-29FB-4314-98E8-E9FC4056F085Q34807402-6C91551E-597D-49FD-B00A-B108E64A23CEQ35096149-C48FC285-F7CA-4E9A-B040-3B0892CA756EQ35211723-DF421672-FAE3-4AA5-827D-DE81B298F707Q35688154-0EA7C7F3-8531-4BA6-914F-8A9FDECADFD4Q35706611-7F53B058-C1D7-477B-8A88-6DF940A851B1Q35741647-1FFEB7D9-C7F8-4BCE-9BCA-5A0A362595E7Q35764986-CE8755F8-2E78-47FB-8092-28DA498B480EQ35790108-FBF4E3B2-37E3-48A1-9737-8414F30F3ABBQ35868145-12D796EE-AA74-4F97-8CFA-187A9366366CQ36010440-63937614-204C-4217-9BE3-ABDC7C4E063AQ36025180-BF81901C-6DE1-45D5-95EB-C890D577FBC4Q36035812-79BC4EDF-4B94-47F6-A077-CC29F717E5E6
P2860
Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy
description
2013 nî lūn-bûn
@nan
2013 թուականին հրատարակուած գիտական յօդուած
@hyw
2013 թվականին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Discovery and validation of a ...... ollowing radical prostatectomy
@ast
Discovery and validation of a ...... ollowing radical prostatectomy
@en
Discovery and validation of a ...... ollowing radical prostatectomy
@nl
type
label
Discovery and validation of a ...... ollowing radical prostatectomy
@ast
Discovery and validation of a ...... ollowing radical prostatectomy
@en
Discovery and validation of a ...... ollowing radical prostatectomy
@nl
prefLabel
Discovery and validation of a ...... ollowing radical prostatectomy
@ast
Discovery and validation of a ...... ollowing radical prostatectomy
@en
Discovery and validation of a ...... ollowing radical prostatectomy
@nl
P2093
P2860
P50
P3181
P1433
P1476
Discovery and validation of a ...... ollowing radical prostatectomy
@en
P2093
Anamaria Crisan
Anirban P Mitra
Benedikt Zimmermann
Christine Buerki
Eric J Bergstralh
George Klee
Ismael A Vergara
Mercedeh Ghadessi
Peter C Black
R Jeffrey Karnes
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0066855
P407
P577
2013-01-01T00:00:00Z